

## COMPOSITION

**Semaglut 3 Tablet:** Each tablet contains Semaglutide INN 3 mg.

**Semaglut 7 Tablet:** Each tablet contains Semaglutide INN 7 mg.

## PHARMACOLOGY

Semaglutide is a GLP-1 analogue with 94% sequence homology to human GLP-1. It acts as a GLP-1 receptor agonist that selectively binds and then activates the GLP-1 receptor. It reduces blood glucose through a mechanism where it stimulates insulin secretion and lowers glucagon secretion, both in a glucose-dependent manner.

## INDICATION

It is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Limitations of use:

- Not recommended as first-line therapy for patients inadequately controlled on diet and exercise.
- Has not been studied in patients with a history of pancreatitis.
- Not for treatment of type 1 diabetes mellitus.

## DOSAGE AND ADMINISTRATION

Starting dose is 3 mg once daily for 30 days. After 30 days on the 3 mg dose, increase the dose to 7 mg once daily. Dose may be increased to 14 mg once daily if additional glycemic control is needed after at least 30 days on the 7 mg dose.

Patients are instructed to take it at least 30 minutes before the first food, beverage, or other oral medications of the day (empty stomach) with not more than 4 ounces (120 ml) of plain water only. Waiting more than 30 minutes to eat may increase the absorption of it.

Patients should swallow the whole tablet. Never cut, crush or chew the tablet.



## CONTRAINDICATION

It is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2). It is contraindicated in the patients with a history of hypersensitivity to Semaglutide or any of the excipients in it.

## WARNING AND PRECAUTION

**Pancreatitis:** Discontinue promptly if pancreatitis is suspected. Do not restart if pancreatitis is confirmed.

**Diabetic retinopathy complications:** Patients with a history of diabetic retinopathy should be monitored.

**Hypoglycemia:** Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necessary.

**Acute kidney injury:** Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.

**Hypersensitivity reactions:** Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue it if suspected and promptly seek medical advice.

## SIDE EFFECTS

The most reported side effects are nausea, abdominal pain, diarrhea, decreased appetite, vomiting and constipation.

## USE IN PREGNANCY AND LACTATION

**Pregnancy:** May cause fetal harm.

**Lactation:** During treatment breastfeeding not recommended.

## USE IN CHILDREN

Safety and efficacy of it has not been established in pediatric patients (younger than 18 years).

## DRUG INTERACTION

When initiating Semaglutide, consider reducing the dose of concomitantly administered insulin secretagogue (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia.

Semaglutide delays gastric emptying. In a drug interaction study, levothyroxine exposure was increased 33% when administered with it. So, when co administering oral medications, instruct patients to closely follow its administration instructions. Consider the increased clinical or laboratory monitoring for medications that have a narrow therapeutic index or that require clinical monitoring.

## OVERDOSAGE

In the event of overdose according to the appropriate patient's clinical signs and symptoms, a prolonged period of observation and supportive treatment should be initiated taking into account the long half-life of Semaglutide of approximately 1 week.

## STORAGE

Store below 25°C temperature in a cool and dry place. Protect from light & moisture. Keep out of the reach of children.

## HOW SUPPLIED

**Semaglut 3 Tablet:** Each box contains 10 tablets in Alu-Alu blister pack in Alu-Alu sachet.

**Semaglut 7 Tablet:** Each box contains 10 tablets in Alu-Alu blister pack in Alu-Alu sachet.